Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Thera CS (NQ: NTLA )

14.81 +0.59 (+4.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Thera CS

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
10 Biggest Price Target Changes For Friday
Piper Sandler boosted the price target for Moderna, Inc. (NASDAQ: MRNA) from $246 to $445. Moderna shares fell 1.6% to $409.55 in pre-market trading. Needham cut the price... 
Via Benzinga
Why Shares of Intellia Therapeutics Are Jumping Today
More progress in the pipeline has investors bullish on the company's shares. 
Via The Motley Fool
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. 
Via InvestorPlace
3 Reasons Caribou Biosciences Could Be the Best Gene-Editing Stock for Your Portfolio
The company has a pedigree and a novel approach that could put it at the top of the CRISPR heap. 
Via The Motley Fool
Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week
After rallying on the coattails of Intelllia's breakthrough, these companies have given back their June gains. 
Via The Motley Fool
99 Biggest Movers From Yesterday
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
Via Benzinga
Why Intellia Therapeutics' Stock Is Trading Higher Today
Intellia Therapeutics Inc (NASDAQ:NTLA) is trading si... 
Via Benzinga
Why Intellia Therapeutics Shares Are Trading Higher Today
... 
Via Benzinga
Unusual Options Activity Insight: Intellia Therapeutics
On Friday, shares of Intellia Therapeutics (NASDAQ:NTLA) ... 
Via Benzinga
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding
It's a good time to be a gene-editing company. 
Via The Motley Fool
Russell 2000 Traders Place Bearish Bets Via IWM ETF
The iShares Russell 2000 ETF (NYSE: IWM) has been trading sideways for the better part of the last six months between $211 and its all-time high of $234.53 from March 15. IWM... 
Via Benzinga
WHO Issues Framework For Governance For Gene Editing Technologies
A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or... 
Via Benzinga
A Comprehensive Guide To Genomic ETFs
Given the growing applications of gene-editing, it is a rising market which offers endless opportunities. Growing demand for personalized medicine, solid investments and higher R&D activities will soon... 
Via Talk Markets
Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results
There are still some key unanswered questions for the biotech's promising gene-editing therapy. 
Via The Motley Fool
US Stocks Technical Analysis: AVAV, ESLT, ICE, HDFC, NTLA & NVDA
Elliott Wave Technical Analysis for AeroVironment, Elbit Systems, Intercontinental Exchange, HDFC Bank Limited, Intellia Therapeutics, and Nvidia. 
Via Talk Markets
Is It Too Late to Buy Intellia Therapeutics?
After skyrocketing 68% last week, will this stock keep running higher? 
Via The Motley Fool
Here's Why Regeneron Gained 11% Last Month
The biopharma outfit dropped news that may mean more for the medicine industry than anybody fully understands. 
Via The Motley Fool
2 Reasons to Buy Intellia -- and 1 Big Reason Why I Won't
After the clinical-stage biotech publicized promising data for its gene-editing treatment of a rare and fatal disease, its stock skyrocketed. 
Via The Motley Fool
Stock Market Rally: S&P 500, Nasdaq Hit Highs; Facebook, Tesla, Nio, Intellia, Didi IPO, OPEC+ In Focus
The S&P 500 and Nasdaq hit record highs last week. Facebook hit a $1 trillion market cap. Tesla deliveries jumped. 
Via Investor's Business Daily
Topics Initial Public Offering Stocks
Exposures Fossil Fuels Securities Market US Equities
Here's What Drove Gene Editing Stocks Higher This Week
The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers. 
Via The Motley Fool
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE... 
Via Benzinga
Exposures Product Safety
5 Reasons Alnylam's Still a Top Biotech Stock to Buy Now
Despite a threat from Intellia on the horizon, Alnylam's still in a position to deliver big gains for patient investors. 
Via The Motley Fool
Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders
Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven... 
Via Benzinga
72 Biggest Movers From Yesterday
Gainers Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share. Cuentas Inc. (NASDAQ: CUEN... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
'Halftime Report' Traders Share Their Thoughts On Crispr Therapeutics And Bed Bath & Beyond
Amy Raskin said on CNBC's "Fast Money Halftime Report" that she would hold Crispr Therapeutics AG (NASDAQ: CRSP). She doesn't own the stock, but she owns... 
Via Benzinga
Why Intellia Therapeutics Was a Winner on Wednesday
The company is about to fatten its coffers significantly. 
Via The Motley Fool
In Future CRISPR Gene Editing To Treat Diseases, Says Intellia Co-Founder: CNBC
Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body. What Happened: On Monday,... 
Via Benzinga
Gene Editing Stocks: Why EDIT, CRSP, NTLA Stocks Continue to Soar
Today, gene editing stocks are soaring amid increasingly bullish sentiment in this sector following strong results from Intellia. 
Via InvestorPlace
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.